CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder saving therapeutics for patients with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life.

Cretostimogene grenadenorepvec
(CG0070)

is a targeted oncolytic immunotherapy agent that has shown remarkable efficacy in bladder cancer.

CG Oncology by the Numbers

Active clinical programs

with planned studies soon underway. See current clinical trials.

%

Complete response rate

at any time for CG0070 in combination with KEYTRUDA®

%

Complete response rate

at 12 months for CG0070 in combination with KEYTRUDA®

Investors

Latest News